Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: a real-world experience from a low-middle income country.

[1]  L. Arnaud,et al.  Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. , 2020, Journal of the American Academy of Dermatology.

[2]  S. Simmens,et al.  Long-term outcomes in Juvenile Myositis patients. , 2020, Seminars in arthritis and rheumatism.

[3]  N. McHugh,et al.  Autoantibodies in myositis , 2018, Nature Reviews Rheumatology.

[4]  L. Pachman,et al.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. , 2018, The Journal of pediatrics.

[5]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups , 2017, Arthritis & rheumatology.

[6]  A. Huber,et al.  Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA) , 2017, Pediatric Rheumatology.

[7]  H. Gunawardena.  The Clinical Features of Myositis-Associated Autoantibodies: a Review , 2017, Clinical Reviews in Allergy & Immunology.

[8]  S. Kabra,et al.  Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome , 2016, Rheumatology International.

[9]  L. Rider,et al.  The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis , 2014, Current Rheumatology Reports.

[10]  I. Dvorchik,et al.  Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center’s experience , 2012, Pediatric Rheumatology.

[11]  A. Reed,et al.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis , 2011, Nature Reviews Rheumatology.

[12]  A. Martini,et al.  Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.

[13]  I. Sjaastad,et al.  Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. , 2009, Rheumatology.

[14]  B. Feldman,et al.  Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. , 2008, Arthritis and rheumatism.

[15]  Surjit Singh,et al.  Twelve years experience of juvenile dermatomyositis in North India , 2006, Rheumatology International.

[16]  A. Dyer,et al.  Duration of illness is an important variable for untreated children with juvenile dermatomyositis. , 2006, The Journal of pediatrics.

[17]  B. Feldman,et al.  Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. , 2002, Rheumatic diseases clinics of North America.